What laboratory monitoring schedule is recommended for patients with multiple endocrine neoplasia type 2 (MEN 2)?

Laboratory Monitoring for MEN2 Syndrome

Laboratory monitoring for MEN2 depends critically on the specific RET variant risk classification, with ATA-High/Highest risk variants requiring earlier and more intensive surveillance than ATA-Moderate risk variants.

Risk-Stratified Monitoring Approach

ATA-Highest Risk Variants (e.g., p.M918T - MEN2B)

For the highest risk variants, calcitonin monitoring should begin by age 3 years with annual measurements, and thyroidectomy is recommended within the first year of life. 1

• Medullary Thyroid Cancer (MTC) surveillance:

  • Annual calcitonin starting at age 3 years 2
  • Note: Physiologic calcitonin levels in infancy can be elevated (up to 50 pg/mL) through age 3-5 years, which may cause false-positive results if not interpreted with age-specific reference ranges 1, 2
  • Blood pressure monitoring at all visits 1

• Pheochromocytoma (PCC) surveillance:

  • Annual plasma or urine metanephrines starting at age 11 years 1
  • Blood pressure assessment at every clinical visit 1

• Primary hyperparathyroidism (PHPT) surveillance:

  • Annual serum calcium starting at age 11 years 1
  • PTH measurement only when hypercalcemia is detected (PTH elevations may precede hypercalcemia but are non-actionable in normocalcemic patients) 1

ATA-High Risk Variants (e.g., codon 634)

Annual calcitonin and ultrasound should begin at age 3 years, with thyroidectomy performed by age 5 years or when calcitonin becomes elevated. 2

• MTC surveillance:

  • Annual calcitonin from age 3 years 2
  • Annual thyroid ultrasound from age 3 years 2
  • Surgery indicated when calcitonin is elevated or by age 5 years 2
  • Metastatic disease is rare if serum calcitonin <40 pg/mL 2

• PCC surveillance:

  • Annual plasma or urine metanephrines from age 11 years 1
  • Blood pressure at all visits 1

• PHPT surveillance:

  • Annual serum calcium from age 11 years 1
  • Codon 634 variants carry 20-30% lifetime risk of PHPT 2

ATA-Moderate Risk Variants (All others)

For moderate-risk variants, annual calcitonin monitoring should begin at age 5 years, with surgery deferred until calcitonin is persistently elevated, particularly approaching or exceeding 20 pg/mL. 1

• MTC surveillance:

  • Annual calcitonin starting at age 5 years 1
  • Calcitonin near upper limit of normal should be repeated every 6 months 1
  • Surgery indicated when calcitonin persistently elevated and increasing, ideally before exceeding 20 pg/mL (the threshold below which lymph node metastases are rarely observed) 1
  • Thyroid ultrasound is NOT recommended for routine surveillance (calcitonin is more sensitive for detecting C-cell hyperplasia to microscopic MTC transition) 1
  • Ultrasound should only be performed when calcitonin is elevated/increasing for operative planning 1

• PCC surveillance:

  • Annual plasma or urine metanephrines from age 16 years 1
  • Blood pressure at all visits 1
  • Risk of PCC is 10-50% depending on specific variant 2

• PHPT surveillance:

  • Annual serum calcium from age 16 years 1

Post-Thyroidectomy Monitoring

After thyroidectomy, annual calcitonin monitoring should continue indefinitely. 1

• Annual calcitonin measurements 1
• Thyroid ultrasound only necessary if calcitonin is increasing 1
• Continue annual screening for PCC and PHPT per age-appropriate guidelines above 1

Critical Pitfalls to Avoid

• Do not measure calcitonin before age 3-5 years in highest-risk variants due to physiologically elevated levels that cause false-positives 1, 2
• Do not routinely perform thyroid ultrasound in moderate-risk variants as calcitonin is the superior surveillance tool 1
• Do not measure PTH routinely - only check when hypercalcemia is detected, as isolated PTH elevation without hypercalcemia is non-actionable 1
• Always screen for pheochromocytoma before any thyroid surgery to avoid hypertensive crisis 3
• Recognize that pheochromocytoma typically develops later than MTC (often 4th-5th decade), but has been reported as early as age 8 years 2, 3